Abstract
Introduction: Survival of extensive disease small-cell lung cancer (ED-SCLC) is generally poor.Some clinical trials performed in several countries showed that overall survival (OS) of ED-SCLC was from about nine to twelve months.The relation between some clinical nor laboratory findings at starting chemotherapy and OS has not been proved yet. Aims and Methods: We intended to reveal whether the clinical or laboratory findings at the time of starting systemic chemotherapy would affect OS of ED-SCLC.We retrospectively checked medical records of 96 ED-SCLC patients, who received systemic chemotherapy in our institution from January 2007 to December 2015. Background: We classified the clinical and laboratory findings of the ED-SCLC patients before administrating systemic chemotherapy as follows:ages less than 70 years or over, sex, good PS (0-1) or poor PS (2-4), elevation of tumor markers (Pro-GRP and NSE) and LDH above their standard values, presence of pleural effusion, distant metastasis in brain, liver or bone. Result: Median OS from the first day of chemotherapy, analyzed at January 2016, was 259 days (95% confidence interval 222-313).The univariate analysis by logrank-test showed that statistical difference in shorter OS was observed in elder ages, poor PS, existence of bone or liver metastasis, and elevation of LDH. In a multivariate analysis these five selected variables, the factors significantly associated with shorter OS were poor PS (p<0.0001, HR3.81,95% C.I. 2.12-6.85), existence of bone metastasis (p<0.05, HR1.71, 95% C.I. 1.10-2.66) and liver metastasis (p<0.005, HR2.22, 95% C.I. 1.35-3.64). Conclusion: Poor PS, bone and liver metastasis were demonstrated to be the independent poor prognostic factors.We also concluded that brain metastasis did not play as a poor prognostic factor because most cases with brain metastasis received whole brain radiation therapy, and some cases with bone metastasis might improve their survival by receiving palliative radiation therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.